Aprio Wealth Management LLC Has $209,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Aprio Wealth Management LLC lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 15.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 868 shares of the medical instruments supplier’s stock after selling 164 shares during the period. Aprio Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $209,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at $27,000. Scarborough Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $32,000. Rise Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at about $38,000. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth about $45,000. Finally, Abound Wealth Management lifted its position in Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $237.17 on Wednesday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52. The firm has a 50-day moving average of $236.65 and a 200 day moving average of $235.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The firm has a market cap of $68.54 billion, a P/E ratio of 52.24, a PEG ratio of 1.92 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.96 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a $0.95 dividend. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent research reports. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.